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Abstract
Background: At present, available pneumococcal vaccines have failed to eradicate infections caused by S.
pneumoniae. Search for effective vaccine continues and some serotype independent pneumococcal proteins are
considered as candidates for the design of new vaccines, especially a mucosal vaccine, since pneumococci enter
the body through mucosal surfaces. Selection of the appropriate adjuvant is important for mucosal vaccines, and
lactic acid bacteria (LAB) with immunostimulant properties are promissory candidates. In this work, we assessed the
adjuvant effect of a probiotic strain, Lactobacillus casei (L. casei), when nasally administered with a pneumococcal
antigen (pneumococcal protective protein A: PppA) for the prevention of pneumococcal infection. Adjuvanticity of
both live (LcV) and heat-killed (LcM) was evaluated and humoral and cellular antigen-specific immune response
was assessed in mucosal and systemic compartments. The potential mechanisms induced by nasal immunization
were discussed.
Results: Nasal immunization of young mice with PppA+LcV and PppA+LcM induced anti-PppA IgA and IgG
antibodies in mucosal and systemic compartments and levels of these specific antibodies remained high even at
day 45 after the 3rd Immunization (3rd I). These results were correlated with IL-4 induction by the mixture of
antigen plus LcV and LcM. Also, PppA+Lc (V and M) induced stimulation of Th1 and Th17 cells involved in the
defence against pneumococci. The protection against pneumococcal respiratory challenge at day 30 after the 3rd I
showed that PppA+LcV and PppA+LcM immunizations significantly reduced pathogen counts in nasal lavages
while prventing their passage into lung and blood. Survival of mice immunized with the co-application of PppA
plus LcV and LcM was significantly higher than in mice immunized with PppA alone and control mice when
intraperitoneal challenge was performed. No significant differences between the treatments involving LcV and LcM
were found.
Conclusions: Live and heat-killed L. casei enhanced the antigen-specific immune response when administered
nasally with a pneumococcal antigen. Considering the potential risk associated with live bacteria, the design of a
nasal vaccine based on pneumococcal antigens and heat-killed L. casei emerges as a safe and effective strategy for
the prevention of pneumococcal infections and opens new possibilities of application of dead LAB as adjuvants in
vaccine formulations against other pathogens.
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Pneumococcal infections are one the most common dis-
eases in both developed and developing countries [1,2].
Despite the widespread use of antibiotics, the emergence
of antibiotic resistant Streptococcus pneumoniae strains
and some problems associated with vaccines have made
pneumococcal diseases a major health problem world-
wide. At present, there are two types of pneumococcal
vaccines in use: capsular polysaccharide pneumococcal
vaccines (PPV) and protein-polysaccharide conjugate
pneumococcal vaccines (PCV). PPV are not effective in
elderly people, immunocompromised individuals or chil-
dren under 2 years of age, while PCV are expensive for
application in developing countries as global vaccination
strategies. In addition, recent researches have shown
that serotypes eradicated by PCV are being replaced by
non-vaccine pneumococcal serotypes [3-5]. Thus, new
strategies for the fight against pneumococci are neces-
sary, and pneumococcal proteins conserved among var-
ious serotypes represent novel alternatives to develop
protein-based pneumococcal vaccines (PBPV). In this
sense, some proteins have been identified and their
capacity to afford protection against invasive and
respiratory infections is being studied [6,7] but at pre-
sent no protein-based pneumococcal vaccines (PBPV)
have been licensed. The use of adjuvants is necessary to
reach an adequate mucosal protective immune response
and the selection of safe and effective adjuvants is a cru-
cial point in the design of mucosal vaccines. At present,
the best studied mucosal adjuvants are Cholera toxin
(CT) and E. coli lymphotoxin (LT), which are highly
immunogenic as well as the most effective experimental
adjuvants known today. However, they are also very
toxic and not acceptable for human use [8]. In this
sense, and based on the “intrinsic” immunostimulator
properties and GRAS (Generally recognized as safe) sta-
tus of certain lactic acid bacteria (LAB) strains [9], some
researchers have considered using them as carriers of
different pneumococcal antigens to prevent pneumococ-
cal infections. Previous studies demonstrated that
immunization with some pneumococcal proteins (e.g.
PspA, PsaA, PpmA, PspC) expressed in lactococcus or
lactobacillus strains are able to afford protection against
S. pneumoniae in mouse models [10-14]. In a previous
report, we showed that a recombinant lactococcus
expressing the pneumococcal protective protein A
(PppA), a protein antigenically conserved among differ-
ent serotype strains of S. pneumoniae ( 3 ,5 ,9 ,1 4 ,1 9
and 23) [15], was able to afford protection against pneu-
mococcal infection in a mouse model [16,17]. A recent
work showed that nasal administration of recombinant
Lactobacillus casei expressing PspC was able to reduce
nasal colonization by S. pneumoniae in a mouse model
[ 1 1 ] .H o w e v e r ,t h e r ea r en oi nvestigations concerning
the effect on the immune system of a non-recombinant
lactobacillus associated to pneumococcal antigen. The
potential application of a recombinant strain in humans
still presents aspects that need to be resolved such as
elimination of antibiotic resistance genes, production of
recombinant strains in a controlled system, safety of its
application to children and immunosuppressed indivi-
duals and cost-benefit evaluation of its production, espe-
cially in developing countries. In the last few years, the
use of some LAB strains in the prevention of respiratory
infection has become more evident [18-21]. In this
sense, the oral and nasal administration of live Lactoba-
cillus casei CRL 431 (L. casei), a probiotic strain, was
able to improve the immune response of the host
against respiratory pathogens in a mouse model. The
effect of L. casei was associated with the stimulation of
the innate and adaptative immune response [18,20-22].
In addition, some studies have demonstrated that non-
viable lactobacilli also have immunostimulant properties
in both humans and animals [23-25], so their use in
nasal vaccines is an interesting point to asses. At pre-
sent, only a few articles have assessed the immune effect
of the administration of non- recombinant lactic acid
bacteria associated to a specific antigen [26] and investi-
gations about a pneumococcal antigen associated to
heat-killed LAB have not been reported. Most publica-
tions evaluate recombinant lactic acid bacteria expres-
sing pneumococcal Ag as potential vaccines against S.
pneumoniae [10-14]. In contrast, in this work a new
option, based on non-engineered and non viable lactic
acid bacteria, was explored as a potential strategy for
nasal vaccination against S. pneumoniae.
On the other hand, since S. pneumoniae enters the
host primarily through the respiratory mucosa, vaccina-
tion strategies by the nasal route are of great interest,
especially if we take into account the fact that most vac-
cines delivered parenterally are not completely effective
to induce mucosal immunity [27]. Moreover, the nasal
route proved to be the most effective pathway to induce
protective immunity against the pneumococcus [28-31].
Since the use of probiotics implies an adequate selection
of strains for specific applications [32], we hypothesized
that a combination of pneumococcal antigen with Lacto-
bacillus casei as a nasal adjuvant could be able to trigger
protective immune responses against pneumococcal
infection. On the basis of the above considerations, the
aim of this work was to assess the mucosal and systemic
immune response induced by nasal immunization with a
pneumococcal antigen (PppA) associated to live and
heat-killed Lactobacillus casei and to analyze the possi-
b l ei m m u n em e c h a n i s m si n v olved in its protective
effect.
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Enhancement of protective systemic and mucosal
antibody response by inclusion of live and heat-killed L.
casei in nasal vaccination with PppA
Mucosal IgA and IgG antibodies are important for the
defence against respiratory infections because, while IgA
prevents pathogen attachment to epithelial cells, thus
reducing colonization, IgG promotes phagocytosis and
prevents local dissemination of the pathogen in the
alveoli as well as its passage into blood [33]. At the sys-
temic level, IgG antibodies ensure protection against
invasive disease. To evaluate the effect of PppA, PppA
+LcV and PppA+LcM on specific antibody responses in
the mucosal and systemic compartment, groups of six
mice for each time were immunized i.n. with PppA,
PppA+LcV, PppA+LcM, LcV, LcM and PBS, according
to protocols previously described. Samples of NL, BAL
and serum analyzed on days 0, 14, 28, 42, 58 and 73
showed that nasal immunization of young mice with
PppA, PppA+LcV and PppA+LcM induced specific anti-
PppA IgA and IgG antibodies in three types of samples,
while no detectable values of these specific antibodies
were observed in any of the samples collected from
animals that received LcV, LcM or PBS (Figure 1). In
NL, the levels of IgA and IgG anti-PppA induced by
PppA+LcV and PppA+LcM were very similar and
higher than antibodies levels induced by PppA group,
while in BAL the results were different. Thus, PppA
+LcM tended to higher IgA values than PppA+LcV on
day 42, but no significant differences were obtained. In
addition, PppA+LcM group induced higher specific IgG
levels than PppA+LcV in BAL on day 42 and signifi-
cantly differences were found. In serum, both PppA
+LcV and PppA+LcM treatments induced similar IgA
and IgG anti-PppA levels. Overall, animals that received
PppA alone produced very low mucosal and serum anti-
PppA responses and antibody levels, reaching a small
peak after the third immunization (day 42) and then
decreasing considerably. Thus, immunization with PppA
failed to induce sustained levels of specific antibodies
over time. In contrast, the nasal administration of PppA
+LcV and PppA+LcM significantly increased IgA and
IgG antibody levels compared with PppA and its levels
remained high even a month and a half after the third
immunization. Our results suggest that both LcV and
LcM were able to enhance the specific humoral immune
Figure 1 Immunoglobulin (Ig)A (a) and IgG (b) anti-pneumococcal protective protein A (PppA) antibodies response in nasal and
bronchoalveolar lavages (NL and BAL) and serum of young mice nasally immunized with PppA and PppA associated with live (LcV)
and heat-killed (LcM) Lactobacillus casei CRL 431. Results are expressed as the mean of the optical density (OD) ± standard deviation for
each specific Ig (n = 6 mice/group at each time point). Antibodies were determined using the enzyme-linked immunosorbent assay method and
samples were considered negative for the presence of specific antibodies when OD 493 < 0.1. Results are representative of two independent
experiments. Significant differences with the PppA group were: P < 0.01.
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were associated with a pneumococcal antigen.
Pattern of cytokines induced by nasal immunization
In order to evaluate the cellular T immune response sti-
mulated by nasal vaccination, Th1, Th2 and Th17 cyto-
kines profiles were studied in mucosal and systemic
compartments. In mucosal fluids (NL and BAL), nasal
immunization with PppA+LcV and PppA+LcM
increased IL-2 and INF-g levels (days 28, 42 and 58)
compared with basal values. PppA+LcV induced higher
IL-2 levels than PppA+LcM on days 73 in NL and on
days 28 and 42 in BAL, while INF-g levels on day 58 in
BAL also were higher for PppA+LcV compared to LcM
+PppA (p < 0.05). LcV, LcM and PppA alone showed a
variable pattern of Th1 cytokine induction throughout
the period assessed (Figure 2A, B and 2C); however,
cytokine levels induced by these three groups were
lower than PppA+LcV and PppA+LcM. Both LcV and
LcM were able to induce Th1 cytokines in mucosal
compartments. In serum, PppA+LcV and PppA+LcM
immunizations increased IL-2 levels during all periods
evaluated, while INF-g was increased on days 28, 42 and
58 in both groups. PppA+LcV showed significant differ-
ences with PppA+LcM on day 58 for IL-2 (p < 0.05)
cytokine induction while no differences were found for
INF-g production between the two groups. Immuniza-
tion with PppA alone was not very effective to stimulate
INF-g and this cytokine increased only on day 42 in
mucosal fluids, while in serum it increased only on days
42 and 58. Live (LcV) and heat-killed (LcM) Lactobacil-
lus casei increased Th1 IL-2 and INF-g cytokines on
days 28, 42 and 58 in mucosal fluids while in serum
only INF-g was increased on those three days; however,
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Figure 2 T helper type 1 (Th1) cytokines production in Nasal lavages = NL (A), Bronchoalveolar lavages = BAL (B) and Serum (C) of
young mice stimulated with protective pneumococcal protein A (PppA) and PppA associated with Lactobacillus casei (PppA+LcV and
PppA+LcM). Nasal administration of L. casei was assessed. Non-stimulated young mice that received PBS were also evaluated as controls of
basal cytokine levels (control). Results are expressed as mean ± standard deviation (n = 6 mice/group at each time point). Significantly different
from the control group: *P < 0.01.
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Page 4 of 14these cytokine levels were lower than those induced in
the groups that included L. casei associated with the
pneumococcal antigen.
On the other hand, during almost all periods evalu-
ated, nasal immunization with the different treatments
induced high levels of IL-4 in both mucosal and sys-
temic compartments compared with basal levels (Figure
3A, B and 3C). However, the highest level of this cyto-
kine, which is a marker of the stimulation of Th2 cells,
was obtained with the nasal administration of live and
dead L. casei associated with the pneumococcal protein
PppA. These results are consistent with the specific
humoral response induced in the PppA alone, PppA
+LcV and PppA+LcM groups. In addition, PppA+LcM
induced higher IL-4 values than PppA+LcV (P <0 . 0 5 )
on day 28 in BAL, while no significant differences in
this cytokine were observed for other periods in mucosal
fluids neither in serum. The regulatory IL-10 cytokine
showed a variable behaviour, depending on the
experimental group studied. However, PppA+LcV and
PppA+LcM induced higher values of IL-10 in both
mucosal and systemic compartments during almost all
periods evaluated. This fact would be important to
ensure a balanced immune response against a pneumo-
coccal infection. Finally, IL-17A, which represents acti-
vation of the Th17 cells, was also evaluated (Figure 4A,
B and 4C). This cytokine showed a variable pattern
depending on experimental group and post-immuniza-
tion days considered. In NL and BAL, nasal administra-
tion of LcV, LcM induced an increase of IL-17 levels
with respect to control group, while that LcM also
increase this cytokine on day 73, in NL. In addition, IL-
17 was increased in PppA+LcV and PppA+LcM groups
at days 28, 42 and 58 in both NL and BAL. In contrast,
PppA just induced an increase in IL-17 in NL at day 42.
In serum, the LcV, LcM, PppA, PppA+LcV and PppA
+LcM groups induced a significant increase of IL-17 on
days 42 and 58 compared with the control group.
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Figure 3 Mucosal (nasal = NL (A) and bronchoalveolar lavages = BAL (B)) and systemic (serum (C)) T helper type 2 (Th2) cytokines
production by young mice immunized with different groups of PppA, Lactobacillus casei (Lc) and PppA+Lc vaccines. (see Fig. 2 for
details).
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Page 5 of 14Considering that IL-17 is involved in the defence against
S. pneumoniae, these results are very important. Overall,
the evaluation of different cytokines associated with Th
cells populations showed that both live and heat-killed
L. casei (LcM) was able to exercise an important adju-
vant effect on the specific cellular and humoral immune
response. Thus, a good antigen-specific immune
response was reached with the mixtures: pneumococcal
Ag+LcV and pneumococcal Ag+LcM.
Protection against respiratory tract infection after nasal
pneumococcal challenge
A pneumococcal respiratory infection model was used
to assess nasal and lung colonization as well as
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Figure 4 Serum, Nasal and Bronchoalveolar lavages (NL and BAL) IL-17A production by young mice immunized with different
treatments containing PppA and Lc. (see Fig.2 for details).
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Page 6 of 14dissemination of the pathogen into blood. Nasal immu-
nization with the pneumococcal antigen associated with
live (LcV) and heat-killed (LcM) L. casei was able to
prevent pneumococcal colonization in lung and patho-
gen dissemination in blood, showing negative hemocul-
tures (Table 1). Also, co-administration of PppA with
LcV and LcM significantly reduced pathogen counts in
nasal lavages compared with PppA and control groups.
Also, an important hallmark was that both live and
heat-killed L. casei were able to reduce mucosal coloni-
zation and prevent the passage of pneumococci into
blood, without significant differences between them.
However, pathogen counts in mucosa compartments
were higher than the ones found after antigen specific +
L. casei (LcV and LcM) immunization. PppA+LcV and
PppA+LcM immunizations were able to reduce patho-
gen counts in NL significantly and prevented their pas-
sage into lung and blood. Finally, immunization with
PppA alone induced a lower reduction in the number of
S. pneumoniae in NL and lung compared with the other
experimental groups, except for the control. In addition,
this antigen alone did not prevent pathogen passage into
blood.
Enhanced resistance to systemic pneumococcal challenge
in immunized mice
In order to determine whether the induction of specific
humoral and cellular immune response induced by nasal
immunization with PppA+LcV and PppA+LcM was cor-
related with increased resistance to pneumococcal infec-
tion, young mice were intraperitoneally challenged with
S. pneumoniae serotype 14 four weeks after the third
immunization.
Animals that received the PppA protein alone or PBS
were also evaluated. In both systemic and respiratory
challenge assays, S. pneumoniae serotype 14 was used
because of its high potential for invasive disease and
also because it is the prevalent one in our country.
Young mice immunized with PppA+LcV showed a
survival percentage of 60% on day 21 after challenge
(Figure 5), which was significantly higher compared with
the control group that received PBS (p <0 . 0 1C o x ’s
Mantel Test), in which 100% of the mice died after day
4 post challenge. PppA+LcM showed a survival percen-
tage of 50% with respect to PBS group but no significant
differences were found compared with PppA+LcV. Mice
that received PppA alone showed a survival percentage
of 20%, with no significant differences with control. The
a n i m a l si nt h i sg r o u pd i e db e t w e e nd a y s4a n d6p o s t
challenge. These results demonstrate that both LcV and
LcM are effective as adjuvants when they are associated
with a pneumococcal antigen because PppA+LcV as
well as PppA+LcM immunizations increased resistance
to the systemic challenge with S. pneumoniae serotype
14.
Discussion
The licensed pneumoccocal vaccines (PPV, PCV), for-
mulated as vaccines depending on serotypes, did not
enable the eradication of infections caused by S. pneu-
moniae. A new conjugate vaccine PCV13 includes 6
additional serotypes with respect PCV7 and provides a
broader spectrum of protection than the vaccines men-
tioned above [34]. However, the emergence of new sero-
types as prevalent causes of disease requires the
development of new conjugate vaccines with broader
serotype coverage. In addition, the high cost of conju-
gate vaccines and the prevalence of specific pneumococ-
cal serotypes in different parts of the world are obstacles
that should be taken into consideration and vaccines
should tailored to each geographical region to ensure
the greatest level of protection. In view of the above, the Table 1 Nasal, lung and blood colonization by S.
pneumoniae after respiratory challenge with the
pathogen
Groups S. pneumoniae serotype 14
NL Lung Blood
Control 5.67 ± 0.23
a 6.79 ± 0.12
a’ 4.42 ± 0.21
a’’
PppA 4.98 ± 0.32
b 5.53 ± 0.51
b’ 3.92 ± 0.14
b’’
LcV 4.10 ± 0.18
c 3.16 ± 0.14
c’ <1.5
c’’
LcM 4.26 ± 0.22
c 3.28 ± 0,17
c’ <1.5
c’’
PppA+LcV 2.38 ± 0.21
e <1.5
e <1.5
c’’
PppA+LcM 2.53 ± 0.19
e <1.5
e <1.5
c’’
Mice were immunized with treatments containing PppA, LcV and LcM.
Animals receiving phosphate-buffered saline (PBS) were used as controls.
Results are expressed as log colony-forming units (CFU)/g of lung or log CFU/
ml of nasal lavages (NL) and blood. The lower limits of bacterial detection
were 1.5 log CFU/g of lung and 1.5 log CFU/ml of NL and blood, respectively.
Significant differences among groups were established by using the least
significant difference test (LSD). Means in the table with different letters (a-f,
a’-b’ or a"-b”) were significantly different P < 0.05).
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Page 7 of 14design of vaccines that can afford serotype-independent
protection emerges as a valuable alternative to control
pneumococcal infection around the world. On the other
hand, although the pneumococcus enters the body
through the respiratory tract, all available vaccines are
applied by the parenteral pathway while the mucosal
route would be more convenient. Nasal immunization
against respiratory pathogens has certain advantages
over other pathways of antigen delivery, principally
because it mimics the route of entry of pathogens and
induces a protective immune response in both the local
and systemic compartments. In addition, the cost-bene-
fit analysis as well as their easy and convenient applica-
tion contributes to the selection of nasal vaccines for
immunization against respiratory pathogens. A point to
be considered in mucosal vaccines is the selection of
appropriate mucosal adjuvants because most vaccine
antigens have little or no inherent immunostimulatory
properties. At present, very few adjuvants have been
approved for clinical use [35], which could be partly due
to the cost of development and to the regulatory restric-
tions imposed on vaccine adjuvants [36] to ensure their
effectiveness and safe application to humans. In this
sense, LAB are attractive candidates as potential adju-
vants, since they are generally recognized as safe and
some of them have been proved to have intrinsic adju-
vant properties when administered through the mucosal
route to prevent respiratory infections [18,20-22]. Our
purpose was to assess the adjuvant effect of a specific
live and dead probiotic strain when it is associated with
a pneumococcal antigenic protein. Thus, we studied the
protective effect exerted against S. pneumoniae infection
by nasal immunization with PppA when live (LcV) and
heat-killed (LcM) Lactobacillus casei 4 3 1w a su s e da sa
mucosal adjuvant. The role of PppA in the pathogenesis
of pneumococcal infection is unknown but it presents
homology with a nonheme iron-containing ferritin pro-
tein from Listeria innocua and other bactoferritins.
PppA was able to induce protective antibodies when it
was administered by the nasal route associated with a
mucosal adjuvant [15] or when it was expressed in a lac-
tococcus strain and the recombinant bacterium was
administered by the oral and nasal routes [17,37,38] in a
pneumococcal infection model. When a recombinant
strain was used, the intrinsic adjuvant capacity of Lacto-
coccus lactis [19,39] enhanced the specific immune
response. Although the protection reached in all the
above cases was good, the use of recombinant strains
have some implications that should be considered such
as amount of protein expressed, elimination of ATB
markers in live strains, lower adjuvanticity of inactivated
recombinant strains that make necessary the implemen-
tation of better immunization protocols [37], the design
of adequate protocols for human trials and the cost of
large-scale production of recombinant strains. In addi-
tion, a mixture of proteins may be necessary to achieve
a broad-spectrum vaccine against pneumococcal dis-
eases and obtainment of a recombinant strain that
expresses various proteins could be difficult. All these
aspects should be taken into account for the develop-
ment of a new vaccine and the use of harmless bacteria
as adjuvants emerges as an attractive option. The mix-
ture of different antigens, the control of the concentra-
tion of each in vaccine formulations and the selection of
strains for particular purposes would be some of the
advantages when non-recombinant microorganisms are
used. Moreover, non-engineered microorganisms have
greater acceptability by the general population than
genetically modified ones. Previous reports showed that
nasally administered specific lactobacillus and lactococ-
cus strains were able to improve the protective immune
response against S. pneumoniae [18,19,40,41]. Thus,
Cangemi de Gutierrez et al. [18] demonstrated that the
intranasal administration of L. fermentum isolates from
the pharynx of BALB/c mice was able to activate macro-
phages in the respiratory tract and reduced nasal and
lung colonization of S. pneumoniae. Also, in previous
investigations, we demonstrated that the nasal adminis-
tration of Lactococcus lactis (LL) enhances the protective
immune response against a pneumococcal challenge in a
mouse model [19] and this effect was associated with
the up-regulation of the innate and adaptative immunity
in both the respiratory and the systemic compartments.
In all these studies, live bacteria were used. In contrast,
Hori et al. [41] reported that nasal administration of
killed-heat L. casei Shirota activated the cellular immune
response in the respiratory tract and protected against
Influenza Virus infection. Recently, it was reported that
both live and dead Lactobacillus casei 431, the ones
used in this study, improved protection against pneumo-
coccal infection in malnourished mice [42]. All these
reports studied the immunostimulant properties of spe-
cific strains of lactic acid bacteria alone. In this work,
we demonstrated the adjuvant effect of live and dead L.
casei nasally administered when associated with a pneu-
mococcal antigen. In this sense, considering that the
humoral immune response is extremely important in
the defence against S. pneumoniae, specific anti-PppA
antibodies were evaluated. Thus, nasal immunization of
PppA alone induced low levels of specific IgA and IgG
antibodies while the PppA+LcV and PppA+LcM mix-
tures induced the highest values of antigen-specific anti-
bodies. In a previous report it was demonstrated that
passive immunization of naïve mice with serum from
animals immunized with recombinant Lactococcus lac-
tis-PppA increased the survival percentage against a
pneumococcal challenge [17] and these results showed
that anti-PppA antibodies are important components of
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contribute to a decrease in the colonization of the
respiratory tract by limiting pathogen attachment to the
respiratory epithelium while IgG would have an impor-
tant role as opsonin in the phagocytosis of organisms
[33]. Thus, both types of specific inmunoglobulin are
desirable in vaccination-induced protective immunity.
At the systemic level, the induction of specific IgG was
higher than IgA, as expected, which is important to pre-
vent the systemic dissemination of S. pneumoniae.
Moreover, it was demonstrated that nasal administration
of L. casei live and killed heat increased the anti-pneu-
mococcal IgA and IgG antibodies in the local and sys-
temic compartments after a pneumococcal respiratory
infection [40]. Also, L. casei increased the number and
activation of alveolar macrophages and neutrophils in
BAL. The phagocytosis process involved in the primary
depuration of pneumococci would be facilitated by the
specific antibodies. Overall, the immunostimulatory
effect of the probiotic strain contributes to the strength-
ening of the protective immune response after vaccina-
tion. On the other hand, the nasopharynx-associated
lymphoid tissue (NALT) contains all the immune cells
required for the induction and regulation of the mucosal
immune response to antigens delivered into the nasal
cavity [42]. Hussell and Humphreys [43] suggested that
the NALT could fulfil an important role by reducing the
pathogen burden to a level that only induces minimal
inflammation in the lower lung. In consequence, the
intranasal priming of NALT with L. casei would activate
the immune system and enhance the response against a
specific pneumococcal antigen. At present, studies are
being carried out in the nasopharynx to analyze the
immune mechanisms induced at this level by the pro-
biotic strain alone and associated with pneumococcal
antigens. In previous studies, it was demonstrated that
the oral administration of L. casei induced an increase
in IgA cells in the bronchus-associated lymphoid tissue
(BALT) in lung [44,45]. In contrast, CD4+ and CD8+ T
lymphocytes were not able to migrate to sites distant
from the intestine [9,44,45], although T-cell activation
cannot be excluded as a cytokine source. According to
these results, it seems likely that the direct stimulation
at the nasopharynx level induced the IgA cells from the
NALT, which would favour IgA production in the
induction site and also in lung and serum by the “IgA
cycle”. The adjuvant effect of LcV and LcM over the
specific humoral immune response was evident and it
was coincident with the capacity of this lactobacillus to
induce the Th2-cytokine IL-4 in NL, BAL and serum
when it was nasally administered either alone (live and
dead) or combined with PppA. In addition, the levels of
specific antibodies induced by PppA+LcV and PppA
+LcM immunization remained elevated, even 45 days
after the last immunization, an essential condition for a
vaccine. Nasal colonization is a crucial step in the pro-
gression of a pneumococcal infection and the high levels
of specific antibodies induced by immunization with
PppA+LcV and PppA+LcM in nasal and bronchoalveo-
lar lavages would be involved in the reduction in naso-
pharynx and lung colonization by the pathogen. In this
sense, IL-10 plays a key role in the modulation of the
immune response induced after pneumococcal infection,
limiting the inflammatory immune response and stimu-
lating antibody production. Zhang et al. [46] demon-
strated the regulatory role of IL10 in B-cell antibody
responses against pneumococcal proteins. The authors
suggest that IL-10 and INF-gamma are key regulators of
mucosal anti-pneumococcal protein antibody production
in the nasopharynx and are important in local protec-
tion against pneumococci. On the other hand, in a pre-
vious report, we showed that oral administration of L.
casei beneficially regulates the balance between tumor
necrosis factor-alpha and interleukin 10, allowing a
more effective immune response against infection and
modulating the inflammatory response, with less damage
to the lung [20]. Thus, we considered that IL-10 induc-
tion by PppA+LcV and PppA+LcM would favor the
humoral specific immune response and would regulate
the inflammatory response after pneumococcal infection;
low IL-10 levels would compromise regulation of the
host defense response against infectious challenge. On
the other hand, CD4+ Th cells play a central role in
orchestrating the adaptive immune response and,
although they are historically called helpers by their role
in activating B, their functions are more extended. Thus,
considering that the cellular immune response is very
important in the defence against S. pneumoniae, stimu-
lation of T helper cells was studied on the basis of the
cytokines profile induced by immunization. Our results
showed that PppA+LcV and PppA+LcM immunizations
were able to stimulate INF-g release in NL, BAL and
serum and that LcV and LcM alone induced a similar
effect although to a lesser degree. The INF-g Th1 cyto-
kine enhances chemokine expression and promotes pul-
monary neutrophil recruitment into the infected lung,
playing an important role in the neutrophil-mediated
host protective responses against pneumococcal infec-
tion. IL-2 was increased in mucosa and serum by PppA
+Lc and PppA+LcM immunizations during almost all
the periods assayed and this effect would partly account
for the high level of specific antibodies observed on day
73 after the first immunization. Although the factors
influencing the differentiation of memory cells are
incompletely understood, some investigations support a
role of IL-2 in memory cell differentiation [47,48]. This
cytokine would exert a strong influence on the prolifera-
tive capacity and maintenance of memory cells, which
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efficacious long-term vaccine. Moreover, IL-17 was
increased following PppA+LcVand PppA+LcM vaccina-
tion in both the mucosal and systemic compartments.
Recent studies have demonstrated that IL-17 plays a cri-
tical role in the recruitment of phagocytes that leads to
the clearance of S. pneumoniae colonization from the
mucosal surface of the nasopharynx. In addition, IL-17
would mediate the death of S. pneumoniae in the pre-
sence or absence of specific antibodies [49,50]. Thus, IL-
17 induction by PppA+LcV and PppA+LcM immuniza-
tion would play an important role in the reduction of
colonization and increased survival of the vaccinated
mice in the respiratory and intraperitoneal challenge
assays. In contrast, PppA increased this cytokine only in
NL and serum on some of the days assessed. Recent
reports indicated that vaccine-induced IL-17 enhanced
pathogen death by phagocytic cells through an increase
in chemokines induction by epithelial cells that resulted
in phagocytes recruitment and also by an increase in
antimicrobial peptides implicated in the control of
extracellular pathogens [51].
The induction and maintenance of antigen specific
T-cell responses is an essential feature in the protec-
tion against S. pneumoniae that should be harnessed in
the design of effective mucosal vaccines. The effective-
ness of nasal immunization by combination of PppA
with live and heat-killed L. casei was evident in chal-
lenge assays carried out on day 30, after the third
immunization. Thus, PppA+LcV and PppA+LcM vacci-
nation considerably reduced pathogen counts in NL
and prevented lung and blood colonization when ani-
mals were challenged nasally. In addition, these treat-
ments allowed the survival of 50-60% of the mice after
peritoneal challenge with the pathogen. Immunization
with PppA alone could fail to provide adequate protec-
tion against pneumococcal infection partly because it
does not induce high specific antibody levels but
mainly because it would not be able to stimulate effec-
tor and memory cells in an efficient way. In this sense,
nasal immunization with PppA was not a good inducer
of IL-2, IL-17 and INF-g, which are important factors
in the defence against S. pneumoniae. In contrast, vac-
cination with PppA+Lc (LcV and LcM) was able to
induce a good specific humoral and cellular immune
response in the mucosal and systemic compartments.
Our results indicate that L. casei 431 can act as a good
mucosal adjuvant, allowing a potent specific immune
response when it is associated with a pneumococcal
antigen, and that the viability of the strain is not a cru-
cial condition for stimulating the antigen-specific
immune response. A recent report [52] demonstrated
that nasal immunization of mice with a combination of
PspA5 and whole cell Bordetella pertussis vaccine (wP)
or wP with low levels of LPS (wP low) was able to pro-
tect against a respiratory lethal challenge with S. pneu-
moniae. However, the use of dead lactic acid bacteria
(Gram+) as a nasal adjuvant represents a novel alterna-
tive for the development of mucosal vaccines using
proteic antigens. This is the first report that considers
the association of a specific pneumococcal antigen
with a non-viable probiotic strain as an adjuvant for
the development of a nasal vaccine. In addition, it is
the first study dealing with the possible mechanisms
involved in long-lasting specific systemic and mucosal
immunity induced after nasal vaccination. The use of
dead microorganisms would allow the safe application
of potential vaccines in immunocompromised hosts
and elderly people without the risks associated with
the use of live bacteria [53]. The effect of live Lactoba-
cillus casei 431 as an adjuvant is not comparable with
other studies [10] because “adjuvanticity” is character-
istic of each strain and must be evaluated for a parti-
cular purpose. Thus, the design of a nasal vaccine
based on pneumococcal antigens and heat-killed L.
casei emerges as a safe and effective strategy for the
prevention of pneumococcal infections and opens new
possibilities for the application of dead lactic acid bac-
teria in the protection against other pathogens.
Conclusions
In this work, we demonstrated that nasal immunization
with live and heat-killed Lactobacillus casei associated
to pneumococcal antigen was able to provide effective
protection against pneumoccocal infection in mice. The
results obtained in animal models do not guarantee
their effectiveness in humans; however, they enable the
establishment of scientific bases for subsequent testing
in humans. In this sense, the use of vaccine formulations
containing dead organisms is safer and more attractive
for the design of human clinical trials in the short term.
Methods
Microorganisms and culture conditions
Recombinant E. coli-PppA was obtained in our labora-
tory and the development of this strain was described in
a previous report from our work group [17]. Briefly, the
pppA gene was amplified from the chromosomal DNA
of S. pneumoniae T14 with EC1 and EC2 primers (EC1
(forward): 5’GGGGCCATGGCTTGTAGAATTGAAAA
AAGAA 3’,E C 2( r e v e r s e ) :5 ’GGGGTCGACTAAAC-
CAGGTGCTTGTCCAAGTTC 3’). The PCR product
was purified from agarose gel using home-made silica
beads and treated with the restriction enzymes NcoI and
SalI. Then, the pppA gene was ligated into the NcoI and
SalI sites of pET28b using T4 DNA ligase (Promega). A
recombinant plasmid containing the pppA gene, named
pET-PppA, was first recovered from E. coli DH10B cells
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sion. BL21(DE3) (pET-PppA) cells were grown with
aeration until they reached an OD600 of 0.8 in LB med-
ium supplemented with neomycin (50 μg/ml) and
induced with 1 mM IPTG (isopropyl-b-D-thiogalacto-
pyranoside) (Sigma) for 2 h. Whole-cell lysates were
prepared, cell debris was removed by centrifugation (20
min, 13,000 rpm, 4°C), and the proteins present in the
supernatant were run on a 12% SDS-PAGE gel to con-
firm expression of the recombinant PppA (rPppA).
rPppA was purified from BL21(DE3) (pET-PppA) as
described below.
Lactobacillus casei CRL 431 (LcV) [20,21], obtained
from the CERELA culture collection, was cultured for 8
h at 37°C (final log phase) in Man-Rogosa-Sharpe broth
(Oxoid), harvested and washed with sterile 0.01 M phos-
phate buffer saline (PBS), pH 7.2. The bacterial suspen-
sion was adjusted to the desired concentration (10
9 cell/
day/mouse) for its later administration by the nasal
route. Heat-killed L. casei (LcM) was prepared by heat-
ing bacteria in a water bath at 80°C for 30 min and the
lack of bacterial growth was confirmed using MRS agar
plates.
Streptococcus pneumoniae serotype 14, kindly provided
by Dr. M. Regueira from the Laboratory of Clinical Bac-
teriology, National Institute of Infectious Diseases,
Argentina, was used. Freshly grown colonies of S. pneu-
moniae were suspended in THB and incubated at 37°C
until the log phase was reached [17]. The pathogens
were harvested by centrifugation at 3600 g for 10 min at
4°C and washed three times with sterile PBS. Then, the
cell concentration of the pathogen was adjusted to the
dose used in the respiratory (10
6 cells/mouse) and peri-
toneal (10
8 cells/mouse) challenge assays.
Pneumococcal antigen
Recombinant PppA (rPppA) was purified using a His-
Bind purification kit (Novagen) and visualized by elec-
trophoresis on 12% SDS-polyacrylamide gels, as pre-
viously described [17]. The reagent and PppA solution
were tested by the E-toxate test for LPS (Sigma) and
shown to be below the limit of detection (2 pg/ml).
rPppA concentration was determined by Bradford’s
m e t h o da n d1 0u go ft h i sp r o t e i nw a su s e di ni m m u n i -
zation protocols.
Mice
Three-week-old male and female Swiss albino mice were
obtained from the closed colony at CERELA and each
experimental group consisted of five or six mice for
each period evaluated. During all experiments, animals
w e r es u p p l i e dw i t hb a l a n c e dr o d e n tf o o da n dw a t e rad
libitum. Experiments were approved by the Animal Care
and Ethics committee at CERELA.
Nasal immunization protocol
Young mice were nasally immunized with 30 microlitres
of a mixture of 5 ug of rPppA plus live (LcV) and heat-
killed (LcM) L. casei (10
9 CFU) as the mucosal adjuvant.
LcV and LCM suspension were prepared in PBS. The
immunization was carried out using a protocol that
comprised 3 successive administrations that included
two consecutive days each time with a 14-day interval
between them (days 0-1, 14-15 and 28-29). Groups that
received LcV, LcM, rPppA and phosphate-buffered sal-
ine solution (PBS) were used as controls. Fourteen days
after each immunization and also at days 58 and 73
after the first immunization, samples of nasal and
bronchoalveolar lavages (NL, BAL) and serum were col-
lected. For nasal lavage collection, a catheter attached to
a syringe was inserted into the nostril and a total of 0.3
ml of PBS was injected. This procedure was carried out
twice and the outflow was collected. Then, NL was cen-
trifuged at 8,000 × g for 10 min to remove cell debris
and clarified NL samples were collected. BAL samples
were obtained according to the technique previously
described [17,18]. Briefly, a catheter was inserted into
t h et r a c h e ao ft h em i c ea n dl u n g sw e r er i n s e dt w i c e
with 0.5 mL of sterile PBS. The fluid recovered from
both rinses were pooled and after 10 min of centrifuga-
tion at 900 × g (at 4°C), the supernatants were collected.
All fluids were stored at 70°C until analysis.
Protection assays: respiratory and systemic challenges
with S. pneumoniae
Respiratory infection
Experimental respiratory infection was induced as pre-
viouslydescribed. Thirty days after the 3
rd immunization,
control and immunized mice were challenged intrana-
sally with the pathogen by dripping 25 μlo fa ni n o c u -
lum containing 10
6CFU (log phase) in PBS into each
nostril and allowing it to be inhaled. Mice were killed at
3 days after challenge with S. pneumoniae and their
lungs were excised, weighed and homogenized in 5 ml
sterile peptone water. Also, nasal lavages were collected
as described above. Homogenates and nasal lavages
were diluted appropriately, plated in duplicate on
Columbia sheep blood agar and incubated for 18 h at
37°C; then, the number of colonies was counted. S.
pneumoniae was identified by standard techniques
[17,20] and the results were expressed as log of CFU/g
of organ for lung and CFU/ml for nasal lavages. In addi-
tion, progression of bacterial growth to the bloodstream
was monitored by sampling blood obtained through car-
diac puncture with a heparinized syringe and plating on
blood agar. Bacteremia was reported as CFU/ml.
Systemic infection
Intraperitoneal challenge experiments were carried out
30 days after the third immunization of the animals. S.
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their exponential phase under the conditions described
above, and each mouse was infected intraperitoneally
with 100 ul of PBS containing 10
8 cells of the pathogen.
Each experimental group consisted of 14 mice and sur-
vival was closely monitored for 21 days.
Enzyme-linked immunosorbent assay (ELISA) for anti-
PppA antibodies
Serum and BAL antibodies against PppA protein were
determined by ELISA, according to previous experi-
ments [17,37]. Briefly, plates were coated with rPppA
(100 ul of a 5 ug/ml stock in sodium carbonate-bicar-
bonate buffer, pH 9.6, per well). Non-specific protein
binding sites were blocked with PBS containing 5%
non-fat milk. Samples were diluted (Serum 1:100; BAL
1:20 and NL 1:4) with PBS containing 0.05% (v/v)
Tween 20 (PBS-T). Peroxidase-conjugated goat anti-
m o u s eI g Aa n dI g G( F cs p e c i f i c ;S i g m aC h e m i c a l ,S t
Louis, MO, USA) were diluted (1:500) in PBS-T. Anti-
bodies were revealed with a substrate solution [o-phe-
nylenediamine (Sigma Chemical)] in citrate-phosphate
buffer (pH 5, containing 0.05% H2O2) and the reaction
was stopped by the addition of H2SO4 1M .R e a d i n g s
were carried out at 493 nm (VERSAmax Tunable
microplate reader; MDS Analytical Technologies, Sun-
nyvale, CA, USA) and samples were considered nega-
tive for the presence of specific antibodies when
OD493 < 0.1.
Cytokine concentration
Cytokine concentrations in NL, BAL and serum were
measured by mouse Th1/Th2 ELISA Ready SET Go! Kit
(BD Bioscience, San Diego, CA, USA), including inter-
leukin (IL)-2 and interferon (IFN)-g as Th1-type, IL-4
and IL-10 as Th2-type cytokines. The IL-17A as a
Th17-type cytokine was also measured using the ELISA
kit from e-Bioscience (BD Biosciences). The sensitivity
of assays for each cytokine was as follows: 4 pg/ml for
IL-2, IFN-g and tumour necrosis factor (TNF)-a,a n d2
pg/ml for IL -4 and IL-10 and IL-17 4 pg/ml.
Statistical Analyses
Experiments were performed in triplicate and results
were expressed as mean ± standard deviation (SD).
After verification of a normal distribution of data, sig-
nificant differences between means were determined
by analysis of variance (ANOVA) with Fisher’sl e a s t
significant difference (LSD) post hoc test using the
StatGraphics software (Manugistics, Rockville, MD,
USA). Differences were considered significant at P <
0.05.
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